Search Market Research Report

Discover Our Latest Reports
Discover Our Featured Reports
Discover Top Selling Reports

Drug Delivery in Cancer Market Size, Share Global Analysis Report, 2022–2028

report img

Drug Delivery in Cancer Market By Product (Liposome, PE Gylated Proteins & Polypeptides, Polymer Nanoparticle, Protein–drug Conjugates), By Application (Hospitals & Clinic, Cancer Treatment Centers, Others), and By Region - Global Industry Overview, Market Size, Share, Statistical Research, Market Intelligence, Comprehensive Analysis, Trends, and Forecast 2022–2028

Industry Insights

[205+ Pages Report] According to Facts and Factors, the global drug delivery in cancer market was valued at USD 1527.40 million in 2021 and is predicted to increase at a CAGR of 6.70 % to USD 2253.92 million by 2028. The study examines the market in terms of revenue in each of the major regions, which are classified into countries.

Global Drug Delivery in Cancer Market Size

To know more about this report | Request Free Sample Copy

logoMarket Overview

Cancer is defined as the uncontrolled growth of abnormal cells. Radiation, chemotherapy, and medical procedures are all used in today's disease treatment systems. Traditional drug delivery strategies for malignant cell growth chemotherapy can kill normal growing cells, thus it's only used for the most severe tumors. A targeted drug delivery system (TDDS) is a framework that delivers medication in a controlled manner to a predetermined location. The polymers play a significant role in the development of nanoparticulate transporters for illness treatment, and nanotechnology-based conveyance frameworks have a critical effect on malignancy therapy. Delay in half-life, improved bio-dissemination, extended course season of medication, controlled & supported the arrival of medication, the flexibility of course of organization, and expanded intercellular grouping of medication are just a few of the significant benefits associated with nanotherapeutic drug delivery systems (NDDS). Targeted drug systems based on nanotechnology are successfully able to include precise quantities of therapeutic pharmaceuticals for patients.

However, market expansion in the region is expected to be hampered by a lack of understanding of new medicine systems in underdeveloped regions and a scarcity of competent medical practitioners. Furthermore, the high expenses of cancer research programmers and clinical trials may stifle market development in economically weak nations like Sudan and Somalia. Market penetration in these regions is expected to be hampered by the implementation of severe regulatory rules and the fragile geostrategic scenario that exists in countries like Cuba and Vietnam.

logo Impact of COVID - 19

Pharmaceutical and biotech businesses, as well as governments around the world, are attempting to combat the COID-19 outbreak, from assisting in the development of vaccines to preparing for obstacles in the medication supply chain. Approximately 115 vaccine candidates and 155 compounds are currently being developed in the R&D pipeline. More regularly used medications, such as hydroxychloroquine, have seen a huge increase in demand for COID-19 treatment. Due to the increased demand for these treatments, manufacturers of COID-19 management drugs have a lot of chances, as many developing nations are running out of them. As a result of the demand for vaccine and treatment medications for COID-19, the pharmaceutical and biotechnology industries are likely to increase significantly in the future. As a result, the worldwide drug delivery in the cancer market is likely to be significantly impacted.

The complete research study looks at both the qualitative and quantitative aspects of drug delivery in cancer market. Both the demand and supply sides of the market have been investigated. The demand side study examines market income in various regions before comparing it to all of the major countries. The supply-side research examines the industry's top rivals, as well as their regional and global presence and strategies. Each major country in North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America is thoroughly investigated.

logoSegmentation Analysis

The global drug delivery in cancer market is segregated based on product, application, and region.

In terms of product, in 2020, the Polymer Nanoparticle accounted for the biggest share of the global drug delivery in cancer market. Nanoparticles as innovative drug delivery devices represent a novel cancer treatment strategy. They protect the medications from chemical and enzymatic breakdown by encapsulating them. Long circulation half-lives, fewer adverse effects, and improved pharmacokinetics are all advantages of nanoparticles in medication administration. These particles also have higher permeability, allowing for more efficient medication delivery to cancer tissues. As innovative drug delivery systems, nanoparticles are seen as a possible alternative to standard chemotherapy, which poses a major risk to healthy tissues. Drug efficacy and DNA delivery and targeting are frequently improved using nanoparticle delivery technologies like as liposomes and micelles. The desire for innovative drug delivery systems has grown as the therapeutic qualities of medications have improved.

In terms of Application, cancer centers will have the largest share. The rise in cancer cases around the world, combined with increased awareness of elective treatment options, is expected to drive market expansion for drug delivery systems. Furthermore, the use of nanoparticles to cure ailments in a variety of countries is expected to boost the market growth. The growing number of important main players in the market who are expanding their interest in research and development of drug delivery systems, as well as a growing product portfolio and administrative endorsements, is expected to accelerate market growth even further.

logoReport Scope

Report Attribute


Market Size in 2021

USD 1527.40 million

Projected Market Size in 2028

USD 2253.92 million

CAGR Growth Rate

6.70% CAGR

Base Year


Forecast Years


Key Market Players

Amgen, Teva, UCB (Union Chimique Belge), Roche, Celgene, Sanofi, Merck, Johnson & Johnson, Takeda, Gilead Sciences All Market Inc., and Others

Key Segment

By Product, Application, and Region

Major Regions Covered

North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Purchase Options

Request customized purchase options to meet your research needs. Explore purchase options

logo Regional Landscape

Because of the rising incidences of cancer in the region, as well as the growing elderly population and the resulting need for advanced therapeutic techniques, North America is likely to lead the market. Other key factors driving the growth of this market include an increase in clinical trials for new treatment mechanisms, an increase in drug discovery spending plans, an increase in the number of regional players, an increase in the occurrence of malignancy, and FDA approvals for NDDS business accessibility.

The Asia Pacific market for drug delivery systems in cancer therapy is predicted to increase significantly in the next years, because of rising cancer rates in China and Japan, Japan's growing geriatric population, and joint product development efforts between the US and Japan. Furthermore, it is expected that China will strengthen malignancy examination in the future, raising awareness of noel therapies in East Asia. Due to a large number of cancer patients, increased awareness of noel therapies among cancer patients, and high consumption of medical services, the European market is expected to see significant improvements in the drug delivery sector.

logoCompetitive Landscape

List of Key Players in the Global Drug Delivery in Cancer Market:

  • Amgen
  • Teva
  • UCB (Union Chimique Belge)
  • Roche
  • Celgene
  • Sanofi
  • Merck
  • Johnson & Johnson
  • Takeda
  • Gilead Sciences All Market Inc.

The Global Drug Delivery in Cancer Market is segmented as follows:

logoBy Product Segment Analysis

  • Liposome
  • PE Gylated Proteins & Polypeptides
  • Polymer Nanoparticle
  • Protein–drug Conjugates

logoBy Application Segment Analysis

  • Hospitals & Clinic
  • Cancer Treatment Centers 
  • Others

logoBy Regional Segment Analysis

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Nordic Countries
      • Denmark
      • Sweden
      • Norway
    • Benelux Union
      • Belgium
      • The Netherlands
      • Luxembourg
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Southeast Asia
      • Indonesia
      • Thailand
      • Malaysia
      • Singapore
      • Rest of Southeast Asia
    • Rest of Asia Pacific
  • The Middle East & Africa
    • Saudi Arabia
    • UAE
    • Egypt
    • South Africa
    • Rest of the Middle East & Africa
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America

Industry Major Market Players

  • Amgen 
  • Teva 
  • UCB (Union Chimique Belge) 
  • Roche 
  • Celgene 
  • Sanofi 
  • Merck 
  • Johnson & Johnson 
  • Takeda

Frequently Asked Questions

The global drug delivery in cancer market was valued at USD 1527.40 Million in 2021.
The global drug delivery in cancer market is expected to reach USD 2253.92 Million by 2028, growing at a CAGR of 6.70% during the forecast period.
Some of the key factors driving the global drug delivery in cancer market growth include the worldwide increasing incidence of cancer, availability of research funding, increase in awareness about alternative methods for treatment, and favorable reimbursement scenarios in developed nations are some of the key drivers of this market. In addition, the use of nanoparticles to treat cancers is expected to boost the market growth.
Asia Pacific region held a substantial share of the drug delivery in cancer market in 2021.
Some of the major companies operating in the drug delivery in cancer market are Amgen, Teva, UCB (Union Chimique Belge), Roche, Celgene, Sanofi, Merck, Johnson & Johnson, Takeda, and others.